TransCon PTH Shows Sustained Efficacy, Safety Through 3.5 Years in Phase 3 Hypoparathyroidism Trial
ASND sits 36% above its 52-week low of $160.86.
Summary
Ascendis Pharma announced positive Week 182 (3.5 years) data from its Phase 3 PaTHway trial for TransCon PTH (YORVIPATH) in adults with hypoparathyroidism. The data demonstrated sustained efficacy and safety, with 86% of patients achieving independence from conventional therapy, improved kidney function, normalized biochemistries, and significant improvements in quality of life. This follows recent positive 5-year Phase 2 data for TransCon PTH announced on June 11th, further strengthening the drug's long-term clinical profile. The sustained benefits and safety reinforce the drug's market potential and its position as a key treatment for this chronic condition.
At the time of this announcement, ASND was trading at $218.06 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $13.6B. The 52-week trading range was $160.86 to $250.74. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.